News Release
"06/11 07:46 Sunrise Technologies Rejects Claims
of Sturza Institutional
Research <SNRS.O>
Sunrise Technologies Rejects Claims of Sturza Institutional Research
FREMONT, Calif.--(BW HealthWire)--June 11, 1999--Sunrise Technologies
International, Inc. (Nasdaq:SNRS) today announced it rejects the claims of a
Sturza Institutional Research report issued about the Company on June 7,
1999.
The Company completely rejects Sturza's analysis and findings. Sunrise
charges that the report distorts the clinical data and the Company's business
and prospects and characterized the report as slanted and incomplete. For
example, Sturza's report ignores the impact of the most recent and the most
extensive clinical data that is currently being reviewed by the U.S. Food and
Drug Administration (FDA).
"We welcome fair comment, analysis and critique. Our shareholders and
potential investors deserve the benefits of many differing points of view.
However, we strongly object to writings that are unbalanced, incomplete, and
which attempt to unfairly discredit good science," said C. Russell Trenary III,
President and Chief Executive Officer of Sunrise Technologies International,
Inc.
The Company has asked its outside counsel to conduct an investigation of
the report and share its findings with the Company's Board of Directors no
later than June 30, 1999.
The Company anticipated that as it moved closer to its July 22 date with the
Ophthalmic Devices Advisory Panel, and as positive news became more
frequent and widespread, efforts would be made by a few to take advantage
of its shareholders. "We will be ever vigilant to maintain the integrity of the
Company's market for its stock," added Trenary.
The Ophthalmic Devices Advisory Panel will review the Company's Premarket
Approval (PMA) application on July 22, 1999 for the treatment of hyperopia
(+.75 to +2.50 diopters). Sunrise believes about 31% of Americans over 40
have hyperopia from +.75 to +2.50 diopters.
"We have never been more optimistic about the Company's business,
prospects and people. We believe that our new products will be
enthusiastically received by patients and ophthalmologists alike," said
Trenary.
Sunrise Technologies International, Inc., based in Fremont, is a refractive
surgery company that produces and markets high technology products
revolutionizing treatment methods in eye care.
--30--brm/se*
CONTACT: Sunrise Technologies (Investor Relations)
Ed Coghlan, 510/771-2399
or
Susan Lorigan, 510/623-9001
" |
